Boston Scientific's shares fell 4.1% to $47.81 on Wednesday following a cyberattack that caused a global disruption to its operations, including order processing and shipments. This decline wiped out approximately $2.97 billion in market value. The company, which makes medical devices like pacemakers, disclosed on August 25, 2026, that the incident affected its IT systems and business applications crucial for operations, though it has not yet determined if the impact will be material.
Analysts estimate that the cyberattack could endanger $316 million to $369 million in third-quarter sales, representing a 600-700 basis-point impact, if Boston Scientific's recovery mirrors a similar incident experienced by Stryker, which took about three weeks to resolve. Before the attack, Boston Scientific had projected Q3 sales to increase by 3%-5%, equating to approximately $5.22 billion to $5.32 billion, with adjusted earnings of $0.80-$0.82 per share. The market's value loss was roughly 8.0x to 9.4x higher than the projected revenue risk, highlighting investor uncertainty.
The cyberattack makes Boston Scientific the latest medical device company to face such an issue, following others like Medtronic, Abbott, and Intuitive. Stryker's earlier attack in March had significantly affected its ordering, shipping, and manufacturing for weeks, impacting its first-quarter results. While Boston Scientific is diligently working to restore affected functions, the timeline for full restoration and the exact operational and financial impacts remain unknown, adding uncertainty to its 2026 revenue, margin, and earnings per share outlook.
